Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45
CONMED Corporation
CONMED Corporation CNMD | 0.00 |
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:
CNMD) with a Neutral and raises the price target from $39 to $45.